Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.5 SEK | -2.21% | +5.42% | +107.33% |
Sales 2024 * | 65.65M 6.12M | Sales 2025 * | 138M 12.87M | Capitalization | 822M 76.64M |
---|---|---|---|---|---|
Net income 2024 * | -111M -10.35M | Net income 2025 * | -28M -2.61M | EV / Sales 2024 * | 12.3 x |
Net cash position 2024 * | 11.93M 1.11M | Net Debt 2025 * | 259M 24.14M | EV / Sales 2025 * | 7.83 x |
P/E ratio 2024 * |
-5.15
x | P/E ratio 2025 * |
-4.38
x | Employees | 34 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.48% |
Latest transcript on IRLAB Therapeutics AB
1 day | -1.89% | ||
1 week | +5.42% | ||
Current month | +36.40% | ||
1 month | +35.22% | ||
3 months | +8.36% | ||
6 months | +134.89% | ||
Current year | +107.33% |
Managers | Title | Age | Since |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 12-12-31 |
Chief Executive Officer | 71 | 17-05-05 | |
Nicholas Waters
FOU | Founder | 62 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 15-12-31 |
Rein Piir
BRD | Director/Board Member | 66 | 15-12-31 |
Chairman | 66 | 19-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 15.5 | -2.21% | 8 006 |
24-05-22 | 15.85 | +1.93% | 58,853 |
24-05-21 | 15.55 | -0.32% | 44,096 |
24-05-20 | 15.6 | +2.30% | 66,996 |
24-05-17 | 15.25 | +3.39% | 100,168 |
Delayed Quote Nasdaq Stockholm, May 23, 2024 at 03:21 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.33% | 76.62M | |
+37.74% | 723B | |
+33.22% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+16.72% | 244B | |
+10.14% | 208B | |
-4.29% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- IRLAB A Stock